Evogliptin effectively reduces blood glucose and is well-tolerated as add-on, switch, or initial combination therapy in type 2 diabetes patients.
Does evogliptin reduce blood glucose levels and is it well-tolerated in patients with type 2 diabetes mellitus?
Evogliptin is an effective and well-tolerated option for glycemic control in patients with type 2 diabetes mellitus across various treatment strategies.
Absolute Event Rate: 0% vs 0%
Evogliptin reduces blood glucose levels and is well-tolerated when used as an add-on, as a switch from other dipeptidyl peptidase 4 inhibitors, or as part of an initial combination therapy in patients with type 2 diabetes mellitus.
Hong et al. (Thu,) reported a other. Evogliptin effectively reduces blood glucose and is well-tolerated as add-on, switch, or initial combination therapy in type 2 diabetes patients.